Spatial proteomic and digital pathology biomarkers for response to immunotherapy in advanced melanoma patients
Background: Immune checkpoint inhibitors (ICI) have had a major impact on advanced melanoma patient’s survival. Long term benefit is evidenced with 10-year OS data of 44% and 52% for anti-PD1 and combination anti-CTLA4 and anti-PD1, respectively[1]. Despite these impressive results, about half the patients progress within the first year. Although biomarkers such as PD-L1 expression on melanoma cells and immune inflamed, immune excluded and immune desert immunotypes have been proposed, they are not robust predictive biomarker for immunotherapy benefit.
Authors
- Mikäel J. Pittet (ORCID: https://orcid.org/0000-0002-2060-4691)
- Sébastien Menzinger (ORCID: https://orcid.org/0000-0002-2989-6264)
- Olivier Michielin (ORCID: https://orcid.org/0000-0003-4926-6355)
- Jasmin Alia Terzic (ORCID: https://orcid.org/0000-0003-4393-0577)
- Gürkan Kaya (ORCID: https://orcid.org/0000-0003-4957-549X)
- Assma Ben Aïssa (ORCID: https://orcid.org/0000-0002-8190-9683)
- Ping Cheng (ORCID: https://orcid.org/0000-0001-5440-5941)
- Andrew Janowczyk (ORCID: https://orcid.org/0000-0003-2982-4321)
- Doron Merkler (ORCID: https://orcid.org/0000-0002-0247-2007)
- Michel A. Cuendet (ORCID: https://orcid.org/0000-0002-0754-3425)
- M Kreutzfeldt
- Petros Liakopoulos (ORCID: https://orcid.org/0009-0005-2015-6795)
Institutions
- University of Geneva (CH)
- University Hospital of Geneva (CH)
- Geneva College (US)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100581
- Primary Topic
- Advanced Biosensing Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00